bioMerieux (OTCMKTS:BMXMF) Shares Up 8.3% – Here’s Why

bioMerieux (OTCMKTS:BMXMF) was up 8.3% during mid-day trading on Tuesday. The stock traded as high as $95.00 and last traded at $95.00. Approximately 105 shares were traded during trading, a decline of 71% from the average daily volume of 363 shares. The stock had previously closed at $87.75.

Wall Street Analysts Forecast Growth

BMXMF has been the subject of a number of analyst reports. Zacks Research raised shares of bioMerieux from a “strong sell” rating to a “hold” rating in a research note on Monday, September 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Finally, Morgan Stanley reissued an “underweight” rating on shares of bioMerieux in a research report on Friday, September 11th. Five investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

bioMerieux Stock Performance

The firm’s 50 day simple moving average is $85.10 and its 200-day simple moving average is $86.09.

About bioMerieux

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.